EPISODE · Aug 13, 2021 · 59 MIN
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
from Business Trip · host Greg Kubin & Matias Serebrinsky
Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.In this episode, we discuss:Lars’ experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways’ Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested inLinks to topics discussed in this episode:Compass Pathways, Lars WildeCOMP360SSRI, SNRIChristian Angermayer, Robin Carhart-Harris, Michael PollanVivaneoQuercis PharmaTRD (Therapy-Resistant Depression)Compass Phase 2B TrialJazz PharmaceuticalsCompass Pathways 2 US patentsOregon Psilocybin Therapy Measure 109Read the transcript here.Watch episode 10 on YouTube.Created by Greg Kubin and Matias SerebrinskyHosts: Matias Serebrinsky and Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: River Meditation by Jason Shaw and Thea by Muted Circus
Embed this episode
What this episode covers
Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression. In this episode, we discuss: Lars’ experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways’ Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested in Links to top...
Ready to play
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.